MT-Biological Science

MT-Biological Science (MT-Bio) is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of next-generation multi-functional fusion proteins and antibodies for oncology and immunology. The company leverages its proprietary technology platforms to design therapies that simultaneously target multiple pathways, such as the PD-L1/TGF-beta axis. Its lead candidate, MT-001, is a bifunctional fusion protein currently undergoing clinical evaluation for the treatment of advanced solid tumors. MT-Bio aims to address unmet medical needs by creating more effective and safer biological drugs through innovative protein engineering.